Amorfix Blood Test For vCJD Completes Testing at Second Blood Center in
France

- 39,000 Blood Donations Tested to Date -

TSX: AMF

TORONTO , Oct. 29 /CNW/ - Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, today announced it has achieved 100% specificity (no reproducible false positive results) upon testing 19,000 blood donations for variant Creutzfeldt-Jakob Disease ("vCJD") with the EP-vCJD(TM) Blood Screening Assay at l'Etablissement Français du Sang de Pyrénées Méditerrannée ("EFS-PM") in Montpellier, France .

"Our France study has demonstrated the feasibility of implementing the Amorfix test and has provided confidence that very few blood donors would be falsely identified during routine blood testing as potentially having vCJD" said Dr. George Adams , Chief Executive Officer of Amorfix. "With a new probable case of vCJD just announced by the Italian Ministry of Health, and the second vCJD case in Italy , this disease continues to demonstrate a long latency period prior to symptoms developing. High-risk nations should be preparing to conduct prevalence studies to assess the safety of their blood supply."

The blood samples were collected and tested as part of a large-scale study being conducted to demonstrate the feasibility of routine testing of blood donations for vCJD. A total of 39,000 blood donations have now been tested at two EFS blood transfusion centers in France with a specificity of 99.95%, exceeding the 99.85% specificity required by the UK Blood Transfusion Service.

About vCJD

vCJD is rare and fatal human form of a family of diseases known as transmissible spongiform encephalopathy ("TSE") diseases caused by prions. Other TSEs are bovine spongiform encephalopathy ("BSE") in cattle, scrapie in sheep and goats, and chronic wasting disease in deer, elk and moose. Since 1996, a few hundred people living in or visiting Great Britain and other European countries have been diagnosed with vCJD due to the consumption of BSE-infected meat. People can incubate prion disease for 30 to 50 years and could be capable of transmitting it to others throughout that time. Indeed, it is estimated that more than 20,000 people are currently incubating the disease. Recently, five people have been infected through blood transfusions and thousands of people have received blood fractions made from vCJD-infected plasma. There is a general concern that vCJD is now within the blood transfusion systems and, as a result, a screening assay for blood is urgently required.

About the EP-vCJD(TM) Blood Screening Assay

Approximately 81 million units of blood are collected annually and tested for infectious agents, such as HIV-1 and hepatitis viruses at a cost of more than US$4 billion. Until now, however, there has been no way of protecting the blood supply by testing for vCJD. Amorfix is changing that through the Company's development of EP-vCJD(TM) - a test for the presence of vCJD prions in human blood that allows for the selective detection of prions and not the precursor normal protein.

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, variant Creutzfeldt-Jakob Disease (vCJD) and Cancer. Amorfix's proprietary Epitope Protection(TM) (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix utilizes its computational discovery platform, ProMIS(TM), to predict novel Disease Specific Epitopes ("DSE") on the molecular surface of misfolded proteins. ProMIS(TM) is an "in silico" rational selection approach that can be applied to any protein where the normal folding structure is at least partially known. Amorfix's lead therapeutic programs include antibodies and vaccines to DSEs in ALS, Alzheimer's disease and Cancer. The Company's diagnostic programs include a blood screening test for diagnosis of vCJD and an ultrasensitive method for the detection of aggregated Beta-Amyloid in brain tissue of animal models of Alzheimer's disease, months prior to plaque formation.

Forward-Looking Information

This press release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

%SEDAR: 00022789E

For further information: Dr. George Adams, President & Chief Executive Officer, Amorfix Life Sciences Ltd., Tel: [phone], Fax: [phone], [email protected]; Dr. Neil Cashman, Chief Scientific Officer, Amorfix Life Sciences Ltd., Tel: [phone], Fax: [phone], [email protected]